
Synthorx Stock
Biotechnology
Sign up today and learn more about Synthorx Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Synthorx Stock
Synthorx is a biotechnology company using ground-breaking synthetic biology starting with our novel DNA base pair to discover and develop new protein therapeutics. The company uses new building blocks to create proteins that impart specificity not possible with native proteins. The result is treatments with improved efficacy, better safety, and better convenience for patients. Utilizing proprietary engineered organisms we have the ability to manufacture these improved proteins with high fidelity and the required yield for drug discovery and development. This unique platform expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics, not possible with other technologies.
Investors
Correlation Ventures
Getaround, mParticle, Casper, Earnest, Personal Capital, Imperfect Foods, BlueVine, Alloy, Optimizely, Good Eggs
Funding History
April 2014 | $6.0M |
---|---|
July 2016 | $10.0M |
April 2018 | $63.0M |
Management
Chief Scientific Officer
Marcos Milla
President and CEO
Laura Shawver
Founder and Director
Floyd E. Romesberg
Press
Wall Streets Journal - Dec, 9 2019
Sanofi Chief Signals Focus on Cancer With $2.5 Billion DealHerald Keeper - Jun, 12 2018
Synthetic Biology Market is Determined to Cross US$ 38 Billion By 2020Reuters - Apr, 30 2018
BRIEF-Synthorx Completes $63 Mln Series C Financing Led By OrbiMed- Apr, 30 2018
Synthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin™ CytokinesEndpoints News - Dec, 1 2017
Laura Shawver hits the ground running, scouting new investors for tiny SynthorxPR Newswire (press release) - Nov, 29 2017
Scientists at TSRI and Synthorx Create the First Semi-Synthetic Organism to Encode and Translate Expanded Genetic ...PR Newswire (press release) - Nov, 27 2017
Laura Shawver, Ph.D., Appointed CEO of SynthorxPR Newswire (press release) - Aug, 14 2017
Synthorx Appoints Marcos Milla, Ph.D. as Senior Vice President of ResearchEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase